p53 gene therapy of human breast carcinoma: using a transferrin-modified silica nanoparticles

Breast Cancer

Volumn 23, Issue 1, 2016, Pages 101-110

  Rejeeth, Chandrababu ^a   Kannan, Soundrapandian ^a  

^a BHARATHIAR UNIVERSITY   (India)

Author keywords

Breast carcinoma; Gene delivery; p53; Silica nanoparticles; Transferrin (Tf)

Indexed keywords

PLASMID DNA; PROTEIN BAX; PROTEIN P53; SILICA NANOPARTICLE; SODIUM CHLORIDE; TRANSFERRIN; NANOPARTICLE; SILICON DIOXIDE; TP53 PROTEIN, HUMAN; TRANSFERRIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; TUMOR XENOGRAFT; ZETA POTENTIAL; ANIMAL; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; FEMALE; GENETICS; METABOLISM; NUDE MOUSE; PROCEDURES; TUNEL ASSAY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; FEMALE; GENES, P53; GENETIC THERAPY; HUMANS; IN SITU NICK-END LABELING; IN VITRO TECHNIQUES; MCF-7 CELLS; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; RECEPTORS, TRANSFERRIN; SILICON DIOXIDE; TRANSFECTION; TRANSFERRIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84954197052     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-014-0537-z     Document Type: Article

References (40)

1. Csogor Z, Nacken M, Sameti M, Lehr CM, Schmidt H. Modified silica particles for gene delivery. Mater Sci Eng. 2003;23:93–7.
2. Díaz S, Aravena R, Cárdenas H, Casado ME, Miranda P, Schiappacasse V, Croxatto HB. Contraceptive efficacy of lactational amenorrhea in urban Chilean women. Contraception. 1991;43:335–52.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.
4. Torrenga H, Meijer S, Fabry H, Sijp J. Sentinel node biopsy in breast cancer patients: triple technique as a routine procedure. Ann Surg Oncol. 2004;11:231S–5S.
5. Shokuhi S, Clarke D. Surgical techniques in breast cancer. Surgery. 2007;25:268–71.
6. Asoglu O, Muslumanoglu M, Igci A, Ozmen V, Karanlik H, Ayalp K, Bozfakioglu Y, Kecer M, Parlak M. Breast conserving surgery after primary chemotherapy in locally advanced breast cancer. Acta Chir Belg. 2005;105:62–8.
7. Behr JP. Synthetic gene-transfer vectors. Acc Chem Res. 1993;26:274–8.
8. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol. 2000;18:33–7.
9. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev. 2009;109:259–302.
10. Verma IM, Somia N. Gene therapy: promises, problems and prospects. Nature. 1997;389:239–42.
11. Li PC, Li D, Zhang LX, Li GP, Wang EK. Cationic lipid bilayer coated gold nanoparticles mediated transfection of mammalian cells. Biomaterials. 2008;29:3617–24.
12. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AKR, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science. 2006;312:1027–30.
13. Kraljevic S, Pavelic K. Improved navigation would help to solve two crucial problems in modern drug therapy: toxicity and precise delivery. EMBO Rep. 2005;6:695–700.
14. Qian J, Li X, Wei M, Gao X, Xu Z, He S. Bio-molecule-conjugated fluorescent organically modified silica nanoparticles as optical probes for cancer cell imaging. Opt Express. 2008;16:19568–78.
15. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006;121:159–76.
16. Choi CHJ, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA. 2010;107:1235–40.
17. Cheng P. Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin. Hum Gene Ther. 1996;7:275–82.
18. Miyamoto T, Tanaka N, Eishi Y, Amagasa T. Transferrin receptor in oral cancer. Int J Oral Maxillofac Surg. 1994;23:430–3.
19. Elliot RI, Elliot MC, Wang F, Head JF. Breast cancer and the role of iron metabolism. A cytochemical, tissue culture, and ultrastructural study. Ann NY Acad Sci. 1993;698:159–66.
20. Thorstensen K, Romslo I. The transferrin receptor: its diagnostic value and its potential as therapeutic target. Scand J Clin Lab Invest Suppl. 1993;215:113–20.
21. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.
22. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9:402–12.
23. Vousden KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002;2:594–604.
24. Olivier M, Petitjean A, Marcel V, Petre A, Mounawar M, Plymoth A, de Fromentel P, Hainaut ACC. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 2009;16:1–12.
25. Carson DA, Lois A. Cancer progression and p53. Lancet. 1995;346:1009–11.
26. Ecke TH, Schlechte HH, Schiemenz K, Sachs MD, Lenk SV, Rudolph BD, Loening SA. TP53 gene mutations in prostate cancer progression. Anticancer Res. 2010;30:1579–86.
27. Hirshfield KM, Rebbeck TR, Levine AJ. Germline mutations and polymorphisms in the origins of cancers in women. J Oncol. 2010;2010:297671.
28. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9:862–73.
29. Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck. 2007;29:272–84.
30. Rejeeth C, Kannan S, Muthuchelian K. Development of in vitro gene delivery system using ORMOSIL nanoparticle: analysis of p53 gene expression in cultured breast cancer cell (MCF-7). Cancer Nano. 2012;3:55–63.
31. Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Macmillan RD, Nicholson RI, Ellis IO, Gee JMW. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat. 2010;119:283–93.
32. Rejeeth C, Kannan S, Salem A. Novel luminescent silica nanoparticles (LSN): p53 gene delivery system in breast cancer in vitro and in vivo. J Pharm Pharmacol. 2012. doi:10.1111/j.2042-7158.2012.01547.x.
33. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–9.
34. Son SU, Boyce FM. Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (Adriamycin). Exp Mol Med. 2001;33:46–53.
35. Gautam A, Densmore CL, Melton S, Golunski E, Waldrep JC. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther. 2002;9:28–36.
36. Yanagihara K, Cheng PW. Lectin enhancement of the lipofection efficiency in human lung carcinoma cells. Biochim Biophys Acta. 1999;1472:25–33.
37. Yanagihara K, Cheng H, Cheng PW. Effects of epidermal growth factor, transferrin, and insulin on lipofection efficiency in human lung carcinoma cells. Cancer Gene Ther. 2000;7:59–65.
38. Xu L, Frederik P, Pirollo KF, Tang WH, Rait A, Xiang LM, Huang W, Cruz I, Yin Y, Chang EH. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther. 2002;13:469–81.
39. Xu L, Pirollo KF, Chang EH. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther. 1997;8:467–75.
40. Sasaki R, Shirakawa T, Zhang ZJ, Tamekane A, Matsumoto A, Sugimura K, Matsuo M, Kamidono S, Gotoh A. Additional gene therapy with AdCMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys. 2001;51:1336–45.